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Abstract
Aims/hypothesis—Human islets from type 2 diabetic donors are reportedly 80% deficient in 
the p21 (Cdc42/Rac)-activated kinase, PAK1. PAK1 is implicated in beta cell function and 
maintenance of beta cell mass. We questioned the mechanism(s) by which PAK1 deficiency 
potentially contributes to increased susceptibility to type 2 diabetes.
Methods—Non-diabetic human islets and INS 832/13 beta cells cultured under diabetogenic 
conditions (i.e. with specific cytokines or under glucolipotoxic [GLT] conditions) were evaluated 
for changes to PAK1 signalling. Combined effects of PAK1 deficiency with GLT stress were 
assessed using classic knockout (Pak1−/−) mice fed a 45% energy from fat/palmitate-based, 
‘western’ diet (WD). INS 832/13 cells overexpressing or depleted of PAK1 were also assessed for 
apoptosis and signalling changes.
Results—Exposure of non-diabetic human islets to diabetic stressors attenuated PAK1 protein 
levels, concurrent with increased caspase 3 cleavage. WD-fed Pak1 knockout mice exhibited 
fasting hyperglycaemia and severe glucose intolerance. These mice also failed to mount an insulin 
secretory response following acute glucose challenge, coinciding with a 43% loss of beta cell mass 
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when compared with WD-fed wild-type mice. Pak1 knockout mice had fewer total beta cells per 
islet, coincident with decreased beta cell proliferation. In INS 832/13 beta cells, PAK1 deficiency 
combined with GLT exposure heightened beta cell death relative to either condition alone; PAK1 
deficiency resulted in decreased extracellular signal-related kinase (ERK) and B cell lymphoma 2 
(Bcl2) phosphorylation levels. Conversely, PAK1 overexpression prevented GLT-induced cell 
death.
Conclusions/interpretation—These findings suggest that PAK1 deficiency may underlie an 
increased diabetic susceptibility. Discovery of ways to remediate glycaemic dysregulation via 
altering PAK1 or its downstream effectors offers promising opportunities for disease intervention.
Keywords
Beta cell mass; Diet-induced obesity; Insulin secretion; PAK1; Prediabetes; Type 2 diabetes
Introduction
At the time of diagnosis of type 2 diabetes, overall islet mass and/or function may be 
decreased by more than 50% [1–3], suggesting that the progressive degeneration of 
functional beta cell mass is occurring during the pre-diabetic phase, prior to the development 
of frank type 2 diabetes. Factors causal in the demise of beta cell function and/or mass in the 
face of diabetogenic stress are highly sought after.
Previous studies have implicated the serine/threonine p21 (Cdc42/Rac)-activated kinase 1 
(PAK1) as a positive and required factor in both beta cell function [4–6] and maintenance of 
beta cell mass [7, 8]. For example, multiple reports show that Pak1−/− knockout (Pak1 KO) 
mice fed a standard (non-diabetogenic) diet are glucose intolerant, related to impairments in 
glucose-stimulated insulin secretion from islets ex vivo [4] and serum insulin release in vivo 
[5]. Despite this, Pak1 KO mice did not develop fasting hyperglycaemia nor exhibit 
profound changes in beta cell mass. This contrasts with other reports citing an important role 
for PAK1 in beta cell proliferation and survival ex vivo [7, 8]. Notably though, the 
requirement for PAK1 in beta cell proliferation and survival was identified only under 
conditions of islet stress ex vivo, while the Pak1 KO mice were studied only under standard 
conditions. It remains possible that alterations in beta cell mass would not manifest in the 
Pak1 KO mice until challenged with an additional stress to the pancreatic islets, such as 
chronic consumption of a high-fat diet.
It is established that high-fat diet intake leads to the development of insulin resistance in 
both humans and animals [9, 10] and that beta cells compensate by increasing insulin release 
under fasting conditions to quell the ensuing hyperglycaemia, predominantly through 
expansion of the beta cell mass [11, 12]. However, chronic exposure to saturated fatty acids, 
such as palmitate, promotes the release of pro-inflammatory cytokines which are cytotoxic 
to pancreatic beta cells [13, 14]. In addition, saturated fatty acids generate production of 
reactive oxygen species, leading to endoplasmic reticulum (ER) stress [15], with both 
processes ultimately leading to beta cell apoptosis. Whether PAK1 is involved in the in vivo 
compensatory mechanism to maintain euglycaemia in the face of high-fat diet-induced 
stress, and/or for protecting beta cells from palmitate-induced stress, has remained untested.
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Methods
For further details of all experimental protocols please refer to the electronic supplementary 
material (ESM).
Human islet culture
Pancreatic human islets were obtained through the Integrated Islet Distribution Program 
(ESM Table 1). Human islets recovered after arrival in Connaught Medical Research 
Laboratories (CMRL) medium for 2 h, then were handpicked using a green gelatin filter to 
eliminate residual non-islet material. Human islets were treated with either a cytokine 
mixture (10 ng/ml TNF-α, 100 ng/ml IFN-γ and 5 ng/ml IL-1 β; all purchased from 
ProSpec, East Brunswick, NJ, USA) for 72 h, or glucolipotoxic (GLT) mixture (16.7–25 
mmol/l glucose plus 0.5 mmol/l palmitate; Sigma, St Louis, MO, USA) for 48 h, in glucose-
free RPMI 1640 (Gibco, Carlsbad, CA, USA) medium supplemented with 10% (vol./vol.) 
FBS (HyClone, South Logan, UT, USA) and 1% (vol./vol.) penicillin/streptomycin (Gibco) 
for times indicated in the legends, prior to lysis for immunoblot analysis. mRNA was 
quantified from islets by quantified real-time PCR as described [16].
INS 832/13 cell culture, transient transfection and adenoviral transduction
INS 832/13 cells (gift from C. B. Newgard, Duke University, Durham, NC, USA) (passage 
55–80) were grown in RPMI 1640 medium as described [17]. Cells were cultured under 
GLT conditions for 24 h, transfected with small interfering (si) RNA oligonucleotides 
(siPak1, cat no. S103082926; siCtrl, cat no. 1027310; Qiagen, Valencia, CA, USA) using 
RNAiMAX (Invitrogen, Carlsbad, CA, USA), or transduced by infection of adenovirus rat 
insulin promoter (AdRIP)-hPak1 or AdRIP-Ctrl (Viraquest, North Liberty, IA, USA) at 
multiplicity of infection (MOI) = 100, and subsequently treated with GLTor vehicle 
conditions (fatty acid-free BSA) for 2 h prior to harvest for immunoblot or cell death 
analyses. AdRIP-hPak1 was generated by insertion of the full-length hPak1 cDNA into the 
Ins2-adenoviral vector (gifted by T. Becker and C. B. Newgard, Duke University, Durham, 
NC, USA). Adenoviruses were packaged with EGFP to enable visualisation of infection 
efficiency (Viraquest).
Immunoblotting
Proteins were resolved on 10–12% SDS-PAGE for transfer to Standard PVDF, or 
polyvinylidene difluoride for LI-COR fluorescence imaging (PVDF/FL; EMD Millipore, 
Billerica, MA, USA) membranes for immunoblotting using the following antibodies: Rabbit 
anti-PAK1, phospho extracellular signal-related kinase (ERK1/2T202/Y204), mouse anti-
ERK1/2, B cell lymphoma 2 (Bcl2), and cleaved caspase 3 (Cell Signaling, Danvers, MA, 
USA), phospho Bcl2S70 and rabbit anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (Abcam, Cambridge, MA, USA), mouse anti-tubulin (Sigma); all used at 1:1000 
dilutions. IRDye 680 RD goat anti-mouse and IRDye 800CW goat anti-rabbit (LI-COR, 
Lincoln, NE, USA) antibodies were used at 1:15,000 dilutions, and goat anti-mouse and 
anti-rabbit horseradish peroxidase secondary antibodies (Bio-Rad, Irvine, CA, USA) were 
used at 1:5000 dilutions. All antibodies were validated for specificity based upon predicted 
molecular weight of immunoreactive band, selective loss of signal using siRNA or gain of 
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signal using overexpression, and blocking peptides. Immunoreactive bands were visualised 
with enhanced chemiluminescence (ECL)/Prime (GE Healthcare, Buckinghamshire, UK) 
and imaged using a Chemi-Doc Touch (Bio-Rad). Phosphorylated and total ERK1/2 blots 
were imaged using the Odyssey CLx imaging system (LI-COR).
Animals and diets
All animal procedures/protocols were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee (Indianapolis, IN, USA). Pak1 KO 
mice are a classic whole-body gene-ablation model maintained on the C57BL/6J genetic 
background, generated in-house from breeders originating from Jonathan Chernoff (Fox 
Chase Cancer Center, Philadelphia, PA, USA) [18]. After weaning (at 21 days of age), mice 
were allowed free access to water and standard chow (2018SX Teklad Global 18% Protein 
Extruded Rodent Diet, Harlan Laboratories, IN, USA). Mice were group housed until sorted 
into individual housing after the initial acclimatisation period and the start of the feeding 
study. All mice were housed under standard housing conditions using paper bedding, on a 12 
hr light cycle (7:00 lights on, 19:00 lights off). Paired wild-type (WT) littermates served as 
controls. Male 6-week old WT and Pak1 KO mice were acclimated to commercially 
available low-fat diet (LFD, cat no. D01030107, Research Diets, Brunswick, NJ, USA), 
containing 10% energy from fat, for 2 weeks prior to starting the 45% energy from fat/
palmitate-based ‘western’ diet (WD, cat no. D01030108, Research Diets); both pelleted 
diets.
Serum analytes, i.p. glucose tolerance testing and HOMA-IR
Mice were fasted for 6 h or 16 h prior to i.p. D-glucose (Sigma) injection (2 g/kg body 
weight) for measurements of serum insulin response and i.p. glucose tolerance tests 
(IPGTT), respectively. Glucose measurements were sampled from the tail vein using a 
Hemocue analyzer (Hemocue, Mission Viejo, CA, USA). Serum insulin was quantified 
using a sensitive rat insulin radio immunoassay kit (EMD Millipore). The homeostasis 
model for insulin resistance HOMA-IR was calculated according to Matthews et al [19].
Morphometric assessment of islet cell mass
Mouse islet morphometry was evaluated using anti-insulin immunohistochemical staining of 
pancreatic sections as previously described [20]. Percentage of beta cell area was calculated 
using AxioVision software version LE4.8 (www.zeiss.com/microscopy/en_us/downloads/
axiovision; accessed 8 May 2014); beta cell mass was calculated by multiplying percentage 
of beta cell area with pancreas weight.
Proliferation and immunofluorescent confocal microscopy
Paraffin-embedded pancreatic tissue sections were prepared and assessed as previously 
described [21]. To assess proliferation, three pancreatic sections at least 100 μm apart were 
immunostained with rabbit anti-insulin (1: 500 dilution, Santa Cruz Biotechnology, Dallas 
TX, USA), rabbit antiphospho-Histone 3, Ser10 (pHH3) (1:500 dilution, EMD Millipore) 
and DAPI-stained (Sigma); pancreatic sections were taken from at least three mice per 
group. Alexa Fluor 568 goat anti-rabbit IgG (H+L) (1: 500 dilution, Invitrogen) secondary 
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antibody was used. Sections were scanned using a Nikon TiE inverted microscope (Nikon, 
Melville, NY, USA). More than 2000 total insulin-positive cells were counted per pancreas. 
Results were expressed as the percentage of cells positive for all three stains relative to the 
total number of insulin-positive cells. Guinea pig anti-glucagon (1:500 dilution, EMD 
Millipore) was used for staining of alpha cells (ESM Fig. 1).
Cell death assay
Apoptosis was measured from INS 832/13 cells treated with GLT stress by assessment of 
DNA fragmentation and histone release from the nucleus using the Cell Death Detection 
ELISA Plus kit (Roche Applied Science, Indianapolis, IN, USA) [22]. Absorbance was 
measured at 405 and 490 nm from all samples in duplicate and cell death calculated as per 
manufacturer’s instructions.
Statistical analysis
Data are expressed as the mean± SEM. Statistical comparisons were made by two-tailed 
Student’s t test or ANOVA, using GraphPad Prism Version 6.0 (GraphPad Software, La 
Jolla, CA, USA).
Results
Human islets subjected to diabetogenic stressors exhibit reduced PAK1 protein 
expression
To determine whether the loss of PAK1 protein reported in type 2 diabetic human islets 
could be recapitulated in vitro with diabetogenic stressors, islets from non-diabetic human 
donors were subjected to pro-inflammatory cytokines or GLT conditions. Cytokine treatment 
decreased PAK1 protein abundance by 23% compared with vehicle-treated islets from the 
same donor (Fig. 1a). Cytokine action was validated by detection of inducible nitric oxide 
synthase (iNOS) induction, a reporter of inflammatory stress in islets [23, 24] (data not 
shown). GLT stress decreased PAK1 by 28%, and significantly increased expression of 
cleaved caspase 3 (Fig. 1b,c). To obtain enough islets for these paired studies, islets from 
obese donors were also used (ESM Table 1), and all responded to the diabetogenic stimuli 
with reduced PAK1. Pak1 mRNA was reduced by 43% from type 2 diabetic islets compared 
with non-diabetic islets (Fig. 1d). These results indicate that diabetogenic stressors likely 
contribute to the apoptosis and attenuated PAK1 protein levels seen in type 2 diabetes human 
islets.
Pak1 KO mice fed WD exhibit fasting hyperglycaemia with insulin insufficiency
To first confirm that the WD-diet was obesogenic, food intake and body weight were 
monitored throughout the 13-week feeding period. Because of the inherent variability in 
source components for chow, we used a semi-purified, palmitate-based LFD. Although there 
was no difference in grams of food intake (data not shown), the WD-fed Pak1 KO and WT 
mice consumed significantly more energy daily and cumulatively (~40% more) than the 
LFD-fed mice (Fig. 2a). Accordingly, the WD-fed mice showed a larger per cent increase in 
body weight, with equivalent increases between Pak1 KO and WT mice (Fig. 2b). Adipose 
tissue was significantly increased in the WD-fed mice vs LFD-fed mice (Table 1). IPGTT 
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after a 16 h fast showed the WD-fed Pak1 KO mice to have substantially elevated fasting 
blood glucose concentrations (Fig. 2c,d). LFD-fed mice were heavier and less glucose 
tolerant than expected, based upon comparisons with chow-fed mice. As our LFD-induced 
data were similar to another study using these diets [25], this appears to be a feature of the 
palmitate-containing LFD.
Consistently, after just a 6 h fasting period, WD-fed Pak1 KO mice again displayed elevated 
fasting blood glucose levels relative to that of WD-fed WT mice (Fig. 3a); the same WD-fed 
Pak1 KO mice also failed to show increased serum insulin levels upon glucose injection 
(index: glucose-stimulated/basal insulin levels) (Fig. 3b). By contrast, WD-fed WT mice 
mounted a substantial insulin response, as previously shown [26]. LFD-fed Pak1 KO or WT 
mice showed insulin responses similar to chow-fed WT mice (LFD-fed Pak1 KO 1.35 
± 0.15; LFD-fed WT 1.15 ± 0.11; chow-fed WT 1.26 ± 0.17), suggesting that the LFD-diet 
did not negatively impact islet responsiveness to glucose. WD-fed Pak1 KO mice show 
increased insulin resistance compared with WD-fed WT mice, as calculated by HOMA-IR 
(Fig. 3c). These phenotypic data suggest that the WD-fed Pak1 KO mice were unable to 
mount a sufficient insulin response to manage the elevated glucose load induced by WD-
feeding.
Pak1 KO mice show no WD-induced gain in beta cell mass
Given the insulin insufficiency seen in the WD-fed Pak1 KO sera, the corresponding 
pancreases were evaluated ex vivo for changes in beta cell mass relative to LFD- and WD-
fed WT mice. WD-fed Pak1 KO islet beta cell area was visibly diminished relative to WD-
fed WT mice (Fig. 4a). At ~0.83% beta cell area, the WD-fed WT beta cell area exceeded 
the 0.67% beta cell area of the LFD-fed WT mouse pancreas (Fig. 4b, n = 3 pancreases per 
group, p = 0.054). Beta cell area was reduced to ~0.45% in WD-fed Pak1 KO mouse islets 
(red bar), a significant 46% loss relative to the WD-fed WT mice. Calculating beta cell 
mass, which takes into account total pancreas weight, WD-fed Pak1 KO mice were 43% 
deficient, relative to WD-fed WT mass (Fig. 4c). Glucagon-staining was visibly similar 
among all groups (ESM Fig. 1). Thus, unlike the WT mice, the Pak1 KO mice showed no 
WD-induced gain in beta cell area or mass.
Decreased beta cell replication in WD-fed Pak1 KO mice
To determine if loss of beta cell mass in WD-fed Pak1 KO mice was related to defects in 
replication, pHH3 staining was evaluated [26]. While pHH3-stained cells were detected in 
insulin-stained islet cells from WD-fed WT mice, no pHH3-positive cells were seen in an 
equivalent number of beta cells from WD-fed Pak1 KO mice (Fig. 5a,b). Moreover, while 
WD-fed Pak1 KO mice had 35% fewer insulin-staining beta cells per islet (Fig. 5c), the 
number of islets was similar among all groups (Fig. 5d). These results suggest that PAK1 is 
required in the WD-induced beta cell replication.
PAK1 deficiency exacerbates the effects of glucolipotoxicity upon beta cell demise
INS 832/13 cells were exposed to GLT stress as a means to interrogate the mechanism(s) 
underlying the beta cell mass differences in the mice. Prior reports of PAK1 signalling 
downstream to ERK were tested for involvement [4, 6]. After 24 h of GLT treatment, INS 
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832/13 cells exhibited substantial cell death, as determined by the presence of cytosolic 
nucleosomal fragments [22] (Fig. 6a), and a sevenfold increase in cleaved caspase 3 in GLT-
treated cells (Fig. 6b). Concurrent with this, cells had 30% less PAK1 protein, and >60% 
reductions in phosphorylated ERK1/2 (pERK1/2), a downstream target of PAK1 in beta 
cells, and pBcl2, an anti-apoptotic factor (Fig. 6b). These results suggest links between 
PAK1 abundance and ERK1/2 and Bcl2 signalling in GLT-induced beta cell stress.
To determine whether PAK1 depletion exacerbates the effects of GLT upon apoptosis, 
perhaps in an additive manner, the GLT exposure time was limited to just 2 h in cells 
transfected with scrambled (Ctrl) or Pak1 siRNAs. GLT exposure for just 2 h did not 
significantly reduce PAK1 protein levels, permitting separation of GLT effects from PAK1 
depletion. The combined effect of Pak1 siRNA with 2 h GLT stress exerted a significant 
increase in cell death over that of depletion or GLT stress alone (Fig. 7a). PAK1 depletion 
resulted in reduced levels of pERK1/2 and pBcl2 (Fig. 7b).
Consistent with a role in cell survival/anti-apoptosis, PAK1 overexpression protected cells 
from GLT-induced cell death (Fig. 8a). PAK1 overexpression increased pERK1/2 levels only 
slightly (Fig. 8b), perhaps suggesting that ERK1/2 phosphorylation was maximised under 
our serum-containing cell culture conditions (serum contains growth factors that activate 
ERK1/2). PAK1 overexpression significantly increased levels of phosphorylated Bcl2.
Discussion
In this report we demonstrate that increased PAK1 abundance can protect beta cells against 
GLT-induced cell death, and that this is linked through phosphorylation of the anti-apoptotic 
factor Bcl2. Our studies suggest that in the islet beta cell, chronic exposure to GLT stress 
impairs PAK1 abundance, coordinate with attenuated ERK and Bcl2 signalling, and 
increased cell death. In human islets, chronic GLT stress also reduced PAK1 protein and 
increased cleaved caspase 3 expression. Modelling GLT stress in vivo, Pak1 KO mice fed a 
palmitate-rich western diet (WD-fed Pak1 KO) displayed significant fasting hyperglycaemia 
and loss of beta cell mass in just 10 weeks. As such, PAK1 deficiency may underlie an 
increased diabetic susceptibility.
Since the islets of the WD-fed Pak1 KO mice also had decreased beta cell proliferation 
relative to WD-fed WT mice, PAK1 may play multiple roles in the process of beta cell mass 
expansion. The apparent additivity of short-term/acute GLT stress with PAK1 knockdown 
could suggest that GLT induces an early PAK1-independent signal that is insufficient to 
evoke cell death; since PAK1 levels are un-impacted by this, the anti-apoptotic mechanism is 
maintained. Indeed, acute GLT treatment impacts KATP and Ca2+ channel functions in beta 
cells without inducing apoptosis [27, 28]. However, once GLT exposure is prolonged, then 
PAK1 is decreased, and ERK1/2 and Bcl2 are left unchecked to allow apoptosis. Beyond the 
beta cell, PAK1 has been demonstrated to downregulate additional pro-apoptotic factors, 
such as forkhead box in rhabdomyosarcoma (FKHR; also known as forkhead box O1 
[FOXO1]) and Bcl-2-interacting mediator of cell death (BimL) [29–31]. Given the 
possibility that apoptosis effects in clonal beta cells may not fully account for the differences 
in mouse beta cell mass observed, beta cell replication was also evaluated, using mouse 
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pancreases. Our data indicated that PAK1 may be important for beta cell replication and 
survival. Indeed, PAK1 is known to participate in cell cycle progression and mitosis via 
regulating various effectors, such as Aurora-A [32], Polo-like kinase 1 [33] and cyclin-D1 
[34] in other cell types.
Chronically elevated levels of NEFA, principally saturated fatty acids, exert deleterious 
effects on islet beta cells. In vitro, saturated NEFA such as palmitate increase basal insulin 
secretion, decrease glucose-stimulated insulin secretion [35–37] and increase beta cell death 
[22, 38, 39]. Palmitate causes these detrimental effects through multiple mechanisms, such 
as increasing reactive oxygen species, ceramide, and excessive nitric oxide production, as 
well as activation of ER stress pathways [40, 41]. In vivo, healthy beta cells have the 
capability to adapt to elevated serum NEFA levels through mechanisms that are not 
completely understood. However, in genetically pre-disposed beta cells, glucolipotoxicity 
eventually results in beta cell decompensation and dysfunction and ultimately beta cell 
failure [42, 43]; our findings support the concept that PAK1 depletion represents a new type 
of genetic predisposition. The importance of PAK1 in maintaining functional beta cell mass 
during dietary stress becomes clinically relevant when considering that PAK1 protein levels 
in type 2 diabetic human islets are reduced by ~80% compared with non-diabetic controls 
[4] and that the human Pak1 gene is located in the type 2 diabetes susceptibility locus on 
Chromosome 11 [44, 45]. While much more needs to be known to determine whether Pak1 
actually confers the diabetes risk at this site and whether the diabetes risk allele even results 
in decreased PAK1 expression, Pak1 mRNA was reduced by 43% in type 2 diabetic 
compared with non-diabetic and non-obese donor islets. The most appropriate way to 
determine whether Pak1 confers diabetes risk at the sites mentioned may be to examine Pak1 
mRNA and protein in islets from donors (low BMI, obese and type 2 diabetic) known to 
carry the risk allele.
The palmitate-based diet was chosen to mimic the palmitate-rich fast-food diet prevalent in 
western society. This revealed that WD-fed WT could maintain the glucose tolerance profile 
of the LFD-fed WT mice through upregulation of their functional beta cell mass (increased 
insulin release and beta cell expansion). However, that the blood glucose levels remained 
>16.65 mmol/l at 2 h after glucose injection is reminiscent of a peripheral insulin resistant 
phenotype, suggesting that the palmitate-enriched LFD-diet may have generally impacted 
glucose homeostasis. This concept is supported by prior analyses of WT vs Pak1 KO mice 
fed standard chow, wherein WT mice were glucose tolerant and the Pak1 KO mice were 
intolerant [4, 5]. Moreover, in the current study, LFD-fed WT and Pak1 KO mice weighed 
20% more than age-matched chow-fed mice after just 13 weeks of feeding (p < 0.05), 
suggesting that the palmitate-based fat source prompted obesity and insulin resistance. 
Therefore, while on the LFD-diet, it is possible that insulin resistance and subsequent 
glucose intolerance induced by increased weight-gain alone masked the underlying defects 
arising from the PAK1 deficiency.
In this whole-body Pak1 KO model, input from tissues/organs beyond the islet beta cell may 
have contributed to the fasting hyperglycaemia and glucose intolerance of the WD-fed Pak1 
KO mice. For example, in skeletal muscle PAK1 is required for the translocation of GLUT4 
vesicles to the plasma membrane to facilitate glucose clearance, and chow-fed Pak1 KO 
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mice have been shown to display defects in this process [4]. Additionally, a defect in GLP-1 
production and secretion has been reported both in Pak1 KO mice [5, 46] and PAK1-
depleted GLP-1-secreting L cells [47]. As GLP-1 is involved in enhancing glucose-
stimulated insulin secretion, increasing insulin biosynthesis, and promoting maintenance of 
beta cell mass [48, 49], as well as processes external to beta cell [50, 51], it is possible that 
depressed GLP-1 secretion/signalling is contributing to the severe glucose intolerant 
phenotype of the WD-fed Pak1 KO mice. Along these same lines, it has been reported that 
activation of the GLP-1R-signalling pathway in the liver rescues the impaired pyruvate 
tolerance observed in aged Pak1 KO mice [46]. Clarifying the role of PAK1 in the process of 
beta cell compensatory mechanisms will thus require the study of beta cell-specific Pak1 KO 
mice.
In summary, we have demonstrated the requirement of PAK1 in the adaptation of the beta 
cell to the metabolic stress of a palmitate-rich western-style diet. These studies additionally 
suggest that inflammatory- or GLT-stressors carry the capacity to reduce PAK1 protein 
levels in human islets. PAK1 may be a critical factor to target as a means to rescue/enhance 
beta cell mass in response to the stresses encountered during the development of pre- and 
type 2 diabetes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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KO Knockout
LFD Palmitate-based low-fat diet
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1
pHH3 Phospho-Histone H3
siRNA Small interfering RNA
WD 45% energy from fat/palmitate-based ‘western diet’
WT Wild-type
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Fig. 1. 
PAK1 levels are reduced concurrent with increased apoptosis in human islets subjected to 
diabetogenic stressors. Human islets were exposed to (a) pro-inflammatory cytokines 
(IL-1β, TNFα and IFNγ for 72 h; n = 4), or (b, c) GLT stress (glucose at 16.7 mmol/l [b], or 
25 mmol/l [c] with 0.5 mmol/l palmitate for 48 h; n = 3). Proteins detected by 
immunoblotting were quantified relative to GAPDH or tubulin (relative units [RU]). (d) 
Pak1 mRNA levels in type 2 diabetes (T2D) vs non-diabetic donor islets (n = 4 sets each 
type of donor islets), relative to 18SrRNA. *p < 0.05; †p = 0.067
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Fig. 2. 
WD-fed Pak1 KO mice exhibit elevated fasting blood glucose. (a) Food intake (WT-LFD, n 
= 4; WT-WD, n = 3; Pak1 KO-LFD, n = 5; Pak1 KO-WD, n = 4). (b) Body weight (WT-
LFD, n = 6; WT-WD, n = 4; Pak1 KO-LFD, n = 8; Pak1 KO-WD, n = 6). (c) IPGTT 
following 16 h fast (WT-LFD, n = 3; WT-WD, n = 3 Pak1 KO-LFD, n = 4; Pak1 KO-WD, n 
= 4; *p < 0.05 vs LFD). (d) 16 h fasting blood glucose after 10 weeks on WD or LFD. WT-
LFD, white squares/bars; WT-WD, black squares/bars; Pak1 KO-LFD, blue triangles/bars; 
Pak1 KO-WD, red triangles/bars. *p < 0.05, **p < 0.01 and ***p < 0.001
Ahn et al. Page 14
Diabetologia. Author manuscript; available in PMC 2017 January 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
WD-fed Pak1 KO mice exhibit fasting hyperglycaemia, impaired beta cell responsiveness, 
and elevated HOMA-IR. (a) Fasting blood glucose and (b) serum insulin (shown as 
stimulation index; glucose-stimulated/fasted insulin) were measured in 6 h fasted mice after 
11 weeks on WD. Blood was collected prior to and 10 min following glucose injection to 
assess the stimulation index of responsiveness. (c) Insulin resistance, as determined by 
HOMA-IR [19]. Data represent the average ± SEM of 3–6 mice per group. *p < 0.05; **p < 
0.01; ***p < 0.001
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Fig. 4. 
WD-fed Pak1 KO mice have decreased beta cell mass. (a) Whole pancreases were fixed and 
immunostained for insulin content (scale bar, 100 μm), from which (b) islet beta cell area 
and (c) islet beta cell mass were calculated. Bar graphs represent the average ± SEM for 
three pancreases per group. *p < 0.05, **p < 0.01
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Fig. 5. 
WD-fed Pak1 KO mice have reduced beta cell replication. (a) Fixed pancreases were stained 
for insulin (green), pHH3 (red) and DAPI (blue); scale bar, 20 μm. (b) pHH3- and insulin-
double-positive cells were normalised per total number of insulin-positive cells for each 
group. No pHH3-stained cells were detected in Pak1 KO pancreases; (c) average total 
number of insulin-positive cells per section; (d) total islet numbers quantified across >9 
sections per group, with three mice per group. *p < 0.05
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Fig. 6. 
Chronic GLT-induced stress reduces PAK1 abundance concurrent with reduced ERK and 
Bcl2 phosphorylation. INS 832/13 cells were subjected to GLT for 24 h and (a) cell death 
was determined by ELISA. (b) Resultant lysates were assessed for PAK1 content, 
phosphorylated (p) and total (t) forms of ERK and Bcl2, and cleaved caspase 3 by 
immunoblot quantification. The bar graph represents the average ± SEM, with vehicle-
treated lysate bands in each of five independent cell passage experiments set equal to 1 and 
GLT-treated protein levels normalised thereto. *p < 0.05
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Fig. 7. 
Combined effects of PAK1 depletion and acute glucolipotoxicity upon beta cell death. INS 
832/13 cells transfected with Pak1 siRNA or control (Ctrl) siRNA were incubated for 46 h 
prior to GLT exposure for 2 h and (a) cell death was determined by ELISA (n = 5–6; abs, 
absorbance). (b) Resultant lysates were assessed for PAK1 content and phosphorylated (p) 
and total (t) forms of ERK and Bcl2. The bar graphs represent the average ± SEM, with 
siCtrl/vehicle-treated lysate bands in each of three independent cell passage experiments set 
equal to 1 and remaining treatment group protein levels normalised thereto. *p < 0.05, **p < 
0.01
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Fig. 8. 
PAK1 overexpression protects against acute GLT-induced cell death. INS 832/13 cells were 
transduced to overexpress human PAK1 using AdRIP-hPAK1 or AdRIP-Ctrl for 46 h prior 
to GLT exposure for 2 h and (a) cell death was determined by ELISA (n = 3; abs, 
absorbance). (b) Resultant lysates were assessed for PAK1 content, phosphorylated (p) and 
total (t) forms of ERK and Bcl2 by immunoblot quantification. The bar graph represents the 
average ± SEM, with AdRIP-hPak1/vehicle-treated lysate bands in each of three 
independent cell passage experiments set equal to 1 and remaining treatment group protein 
levels normalised thereto. *p < 0.05, **p < 0.01; ***p < 0.001
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Table 1
Tissue weights (as % of total body weight)
WT-LFD
n = 6
WT-WD
n = 4
Pak1 KO-LFD
n = 6
Pak1 KO-WD
n = 6
Body weight (g) 34.7 ± 2 38.8 ± 2 33.9 ± 3 38.6 ± 1
Tissue (% body weight)
 Pancreas 0.83 ± 0.07 0.80 ± 0.05 0.91 ± 0.11 0.84 ± 0.04
 Spleen 0.30 ± 0.06 0.30 ± 0.04 0.32 ± 0.10 0.28 ± 0.03
 Kidney 0.67 ± 0.05 0.60 ± 0.07 0.67 ± 0.08 0.59 ± 0.08
 Heart 0.54 ± 0.06 0.46 ± 0.05 0.60 ± 0.13 0.47 ± 0.05
 Lung 0.51 ± 0.07 0.63 ± 0.11 0.70 ± 0.07 0.48 ± 0.07
 Fat 4.17 ± 0.34 5.90 ± 0.30a,b 3.85 ± 0.59 5.22 ± 0.18c,d
 Intestine 1.41 ± 0.20 1.17 ± 0.07 1.26 ± 0.19 1.27 ± 0.15
 Liver 5.43 ± 0.52 4.57 ± 0.14b 4.85 ± 0.31 4.60 ± 0.09d
 Muscle 0.96 ± 0.05 0.73 ± 0.11 0.93 ± 0.07 0.87 ± 0.11
Data represent the average ± SEM
Weights were collected after 13 weeks of feeding the diets indicated, for determination of variables shown Statistically significant differences were 
detected by two-way ANOVA using a Tukey’s multiple comparison test
aWT-WD vs Pak1 KO-LFD;
bWT-WD vs WT-LFD;
c
Pak1 KO-WD vs Pak1 KO-LFD;
d
Pak1 KO-WD vs WT-LFD
Diabetologia. Author manuscript; available in PMC 2017 January 25.
